RAPT Therapeutics (NasdaqGM:RAPT) FY Conference Transcript

Summary of RAPT Therapeutics FY Conference Call Company Overview - Company: RAPT Therapeutics (NasdaqGM:RAPT) - Focus: Developing transformative therapies for high-value inflammatory disorders - Lead Asset: Ozureprobart, a next-generation anti-IgE therapy designed for less frequent dosing and potentially broader efficacy than Omalizumab [1][2] Industry Insights - Market Opportunities: - Food allergy market estimated at over $40 billion - Chronic spontaneous urticaria (CSU) market estimated at over $5 billion in the U.S. [2] - Patient Demographics: Approximately 17 million diagnosed patients with food allergies in the U.S., including 3.5 million children [11] Clinical Development - Phase 2 Studies: - Positive results from a phase 2 study in CSU showing 16-week durability and a best-in-class profile [2][3] - Initiation of phase 2b food allergy study with top-line data expected in the first half of 2027 [2][19] - Phase 3 Plans: RAPT plans to initiate a phase 3 study in CSU before the end of the year [2][22] Financial Position - Funding: Completed a $265 million follow-on offering to extend cash runway to mid-2028 [4] - Cash Runway: Well-funded to support multiple clinical milestones [3] Product Differentiation - Ozureprobart Advantages: - Designed for less frequent dosing (every 8-12 weeks) compared to Omalizumab (every 2-4 weeks) [8][10] - Higher potency and better pharmacokinetics (PK) allowing treatment of patients with high IgE and/or high weight, who are ineligible for Omalizumab [9][10] - Strong intellectual property (IP) with exclusivity until at least 2041 [8] Efficacy and Safety - Clinical Data: - Ozureprobart demonstrated numerically superior efficacy compared to Omalizumab in CSU trials [21][22] - Well tolerated with no serious adverse events (SAEs) or discontinuations reported [22][26] - Market Research: Payers recognize the value proposition of Ozureprobart due to improved compliance and better patient outcomes [10] Regulatory and Market Strategy - Regulatory Approach: Plans to approach regulatory authorities for phase 3 trials in CSU and asthma [22][29] - Market Positioning: Anticipated price premium for Ozureprobart due to differentiated features [11] Future Milestones - Upcoming Data: Top-line data from the phase 2b food allergy study expected in the first half of 2027 [19][28] - Expansion Plans: Sites planned in the U.S., Canada, and Australia for clinical trials [30][31] Conclusion - RAPT Therapeutics is positioned to address significant unmet medical needs in food allergies and CSU with its innovative therapy, Ozureprobart, backed by strong clinical data and a solid financial foundation [1][2][3][4]